The microenvironment in chronic lymphocytic leukemia: Biology and therapeutic translation

Pietro Bulian, Jan Burger

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The recent success of kinase inhibitors targeting the B cell receptor downstream molecules BTK (ibrutinib and PI3K (idelalisib), their characteristic clinical activity with chronic lymphocytic leukemia (CLL) cell redistribution from tissues into the blood, and their unique mechanism, interception of critical CLL - microenvironment interactions and signaling pathways, emphasize that the CLL microenvironment is a critical player in CLL pathogenesis and key for development of new targeted treatment approaches.

Original languageEnglish
Title of host publicationHodgkin and Non-Hodgkin Lymphomas Seen through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy
PublisherFuture Medicine Ltd.
Pages56-71
Number of pages16
Volume2
ISBN (Print)9781780845821, 9781780845845
DOIs
Publication statusPublished - Jun 1 2015

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The microenvironment in chronic lymphocytic leukemia: Biology and therapeutic translation'. Together they form a unique fingerprint.

  • Cite this

    Bulian, P., & Burger, J. (2015). The microenvironment in chronic lymphocytic leukemia: Biology and therapeutic translation. In Hodgkin and Non-Hodgkin Lymphomas Seen through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy (Vol. 2, pp. 56-71). Future Medicine Ltd.. https://doi.org/10.2217/fmeb2014.14.27